Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
316 people get ELGX articles and Market Currents by email alert.
Get email alerts on ELGX »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Endologix Is Priced For AcquisitionAmod Saul • Wed, Nov 7, 2012
-
-
-
Endologix Is Smooth Sailing in Q4Douglas Cress • Wed, Jan 7, 2009 -
Endologix Rejects Elliott Associates' Buyout Bid As Too CheapDouglas Cress • Fri, Nov 14, 2008
-
But Why? Despite Positives, Endologix Shares DownDouglas Cress • Fri, Oct 24, 2008
-
Endologix: Business as Usual as It Considers $98M BuyoutDouglas Cress • Thu, Oct 23, 2008
-
-
-
-
6 'Strong Buy' Small-Cap Stocks Flush With Cash ReservesZetaKap • Tue, Aug 21, 2012 -
-
-
Why I'm Waiting to Buy These 3 Rocketing Revenue Growth StocksKurtis Hemmerling • Tue, Jul 5, 2011 -
-
-
-
-
Big Lineup of Healthcare Stocks Crack the Russell 3000 IndexM. E. Garza • Wed, Jul 1, 2009 -
-
Endologix's CEO Discusses Q3 2012 Results - Earnings Call TranscriptThu, Oct 25, 2012
-
Endologix's CEO Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Endologix's CEO Discusses Q1 2012 Results - Earnings Call TranscriptThu, Apr 26, 2012
-
Endologix's CEO Discusses Q4 2011 Results - Earnings Call TranscriptWed, Feb 22, 2012
-
Endologix's CEO Discusses Q3 2011 Results - Earnings Call TranscriptThu, Oct 27, 2011 • 1 Comment
-
Endologix's CEO Discusses Q2 2011 Results - Earnings Call TranscriptThu, Jul 21, 2011
-
Endologix CEO Discusses Q1 2011 Results - Earnings Call TranscriptThu, Apr 21, 2011
-
Endologix CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Feb 22, 2011
-
Endologix CEO Discusses Q3 2010 Results - Earnings Call TranscriptWed, Oct 27, 2010
-
GlobeNewswire (May 8, 2013)
-
GlobeNewswire (Apr 30, 2013)
-
GlobeNewswire (Apr 16, 2013)
-
GlobeNewswire (Apr 15, 2013)
-
GlobeNewswire (Apr 8, 2013)
-
GlobeNewswire (Mar 11, 2013)
-
GlobeNewswire (Feb 27, 2013)
-
GlobeNewswire (Feb 7, 2013)
-
GlobeNewswire (Jan 28, 2013)
-
GlobeNewswire (Jan 24, 2013)
-
GlobeNewswire (Jan 7, 2013)
-
GlobeNewswire (Jan 3, 2013)
-
GlobeNewswire (Jan 2, 2013)
-
GlobeNewswire (Dec 31, 2012)
-
GlobeNewswire (Dec 31, 2012)
-
GlobeNewswire (Dec 4, 2012)
-
GlobeNewswire (Nov 6, 2012)
-
GlobeNewswire (Oct 25, 2012)
-
GlobeNewswire (Oct 17, 2012)
-
GlobeNewswire (Oct 17, 2012)
ELGX vs. ETF Alternatives
Company Description
Currently, there's no company description for ELGX.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Wednesday, May 1, 9:10 AM
Premarket gainers: IQNT +34%. MSPD +31%. TRLA +14%. FIRE +12%. JRCC +11%. CAAS +8%. DWA +9%. GDOT +8%. CAVM +8%. NAVB +5%.
Losers: HIMX -9%. ELGX -8%. SWI -8%. Comment! [On the Move] - Tuesday, April 30, 5:17 PM Endologix (ELGX): Q1 EPS of -$0.07 misses by $0.01. Revenue of $29.8M (+22% Y/Y) beats by $0.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, April 30, 12:10 AM Notable earnings after Tuesday’s close: ACAS, AFFX, AJG, AMRS, APU, ATLS, AUY, AVB, BCOV, BGC, BLMN, BXP, CAVM, CLD, CRAY, DDR, DENN, DGI, DWA, EEP, EIX, ELGX, ELLI, ENTR, EQR, EZPW, FEIC, FIRE, FISV, FLEX, FMC, FTNT, GDOT, GEVO, GNW, HCBK, HT, HTCH, IACI, INT, JIVE, JLL, JMBA, LEAP, MDU, MERU, MRGE, MSPD, MTW, MWA, MX, NANO, NCR, NUVA, OKE, OKS, PRAA, PRXL, QCOR, QEP, REXX, RGC, RPXC, SGI, SHOR, SIMG, SKT, SM, SONS, STR, SWI, TE, TRMB, TRN, UGI, ULTI, UNTD, UNXL, VNR, VRSK, VRTX, WNC, WRI, WU, XCO Comment! [Earnings]
- Monday, April 29, 5:35 PM Notable earnings after Tuesday’s close: ACAS, AFFX, AJG, AMRS, APU, ATLS, AUY, AVB, BCOV, BGC, BLMN, BXP, CAVM, CLD, CRAY, DDR, DENN, DGI, DWA, EEP, EIX, ELGX, ELLI, ENTR, EQR, EZPW, FEIC, FIRE, FISV, FLEX, FMC, FTNT, GDOT, GEVO, GNW, HCBK, HT, HTCH, IACI, INT, JIVE, JLL, JMBA, LEAP, MDU, MERU, MRGE, MSPD, MTW, MWA, MX, NANO, NCR, NUVA, OKE, OKS, PRAA, PRXL, QCOR, QEP, REXX, RGC, RPXC, SGI, SHOR, SIMG, SKT, SM, SONS, STR, SWI, TE, TRMB, TRN, UGI, ULTI, UNTD, UNXL, VNR, VRSK, VRTX, WNC, WRI, WU, XCO 2 Comments [Earnings]
- Tuesday, April 16, 2:51 PM Endologix (ELGX +0.5%) receives premarket FDA approval for a broadened indication of it's 21Fr profile and smaller EVAR systems, including totally percutaneous endovascular aneurysm repair. The authorization is based on the successful outcome of it's first clinical trial, the PEVAR Trial. Comment! [Healthcare]
- Wednesday, February 27, 5:07 PM Endologix (ELGX): Q4 EPS of -$0.09 misses by $0.06. Revenue of $29.2M (+25% Y/Y) beats by $0.17M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, January 28, 12:37 PM Endologix (ELGX +2.3%) presents data from its clinical trial of a totally percutaneous approach to endovascular abdominal aortic aneurysm repair, says the study demonstrated that the approach is non-inferior to surgical endovascular repair, and also has significantly reduced procedure times and time to hemostasis. The study also demonstrated positive trends toward lower blood loss, less need for pain medication, and shorter lengths of stay. Comment! [Healthcare, On the Move]
- Monday, December 31, 2012, 2:59 PM Endologix (ELGX +1%) says its distribution partner in Japan, Cosmotec, has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the IntuiTrak Delivery System. The IntuiTrak System delivers ELGX's Powerlink anatomical fixation stent graft for the repair of abdominal aortic aneurysms. Comment! [Healthcare, On the Move]
- Thursday, October 25, 2012, 5:32 PM Endologix (ELGX): Q3 EPS of -$0.10 misses by $0.06. Revenue of $26.7M (+20% Y/Y) beats by $0.4M. (PR) Comment! [Earnings, Healthcare]
- Thursday, July 26, 2012, 7:09 PM Endologix (ELGX): Q2 EPS of -$0.09 misses by $0.05. Revenue of $25.5M (+32.8% Y/Y) beats by $0.27M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, June 12, 2012, 1:27 PM Endologix (ELGX +1.8%) pipeline looks impressive, says Oppenheimer. After meeting with management, the firm says ELGX's growth story remains intact and that abdominal aortic aneurysm market volumes and pricing remain solid. The firm thinks the Street is still underestimating the value of the company's Nelix treatment and reiterates a Buy on the stock. Comment! [Healthcare, On the Move]
- Thursday, April 26, 2012, 5:40 PM Endologix (ELGX): Q1 EPS of -$0.07 beats by $0.01. Revenue of $24.5M (+32.2% Y/Y) beats by $1.2M. Shares +0.7% AH. (PR) Comment! [Earnings, Healthcare]
- Monday, April 2, 2012, 12:21 PM Lazard Capital downgrades a number of names in the in the Medical Technology space today due to valuation. Intuitive Surgical (ISRG +0.2%), Endologix (ELGX -5.4%), Allergan (AGN -0.4%), St. Jude Medical (STJ -0.7%) and ZOLL Medical (ZOLL +0.1%) are all cut to Neutral. 1 Comment [Healthcare]
- Wednesday, February 22, 2012, 5:25 PM Endologix (ELGX): Q4 EPS of -$0.06 misses by $0.01. Revenue of $23.4M (+21.9% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
-
Thursday, February 2, 2012, 9:00 AM
Premarket gainers: GMCR +21%. CEDC +21%. MTSN +15%. OMEX +10%. GPS +8%. CNQR +6%. EA +6%. CDNS +6%. QCOM +5%. ELGX +5%. GFA +5%. AUO +4%. KSS +4%. ZNGA +4%. IRE +4%. CMI +3%. K +3%. CPST +3%. JDSU +3%. MA +3%. RENN +3%.
Losers: SD -13%. ANF -12%. ANN -10%. NG -9%. BSX -6%. CI -6%. RCL -6%. UN -5%. MPW +4%. VIA -4%. UL -4%. CHKM -4%. SNE -4%. PCX -4%. PHM -3%. DOW -3%. ANZ -3%. CUK -3%. CCL -3%. NBG -3%. Comment! [On the Move]